0001731122-24-000263.txt : 20240216 0001731122-24-000263.hdr.sgml : 20240216 20240216090647 ACCESSION NUMBER: 0001731122-24-000263 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240213 FILED AS OF DATE: 20240216 DATE AS OF CHANGE: 20240216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dybul Mark CENTRAL INDEX KEY: 0001734805 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38758 FILM NUMBER: 24645914 MAIL ADDRESS: STREET 1: 8974 BAYVIEW DRIVE, CITY: CHESTERTOWN STATE: MD ZIP: 21620 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RENOVARO INC. CENTRAL INDEX KEY: 0001527728 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 452259340 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: CENTURY CITY MEDICAL PLAZA STREET 2: 2080 CENTURY CITY EAST CITY: SUITE 906 LOS ANGELES STATE: CA ZIP: 90067 BUSINESS PHONE: 45 39179840 MAIL ADDRESS: STREET 1: CENTURY CITY MEDICAL PLAZA STREET 2: 2080 CENTURY CITY EAST CITY: SUITE 906 LOS ANGELES STATE: CA ZIP: 90067 FORMER COMPANY: FORMER CONFORMED NAME: RENOVARO BIOSCIENCES INC. DATE OF NAME CHANGE: 20230807 FORMER COMPANY: FORMER CONFORMED NAME: Enochian Biosciences Inc. DATE OF NAME CHANGE: 20230804 FORMER COMPANY: FORMER CONFORMED NAME: Renovaro Biosciences Inc. DATE OF NAME CHANGE: 20230802 4 1 ownership.xml X0508 4 2024-02-13 0 0001527728 RENOVARO INC. RENB 0001734805 Dybul Mark C/O RENOVARO BIOSCIENCES INC. 9480 NE 2ND AVENUE #73 MIAMI FL 33138 1 1 0 0 Chief Executive Officer 0 Option to Purchase Common Stock 5.95 2024-02-13 4 D 0 7563 D 2028-02-28 Common Stock 7563 0 D Option to Purchase Common Stock 1.92 2024-02-13 4 A 0 7563 A 2024-02-13 2028-02-28 Common Stock 7563 7563 D Option to Purchase Common Stock 5.74 2024-02-13 4 D 0 5226 D 2019-02-28 2028-09-19 Common Stock 5226 0 D Option to Purchase Common Stock 1.92 2024-02-13 4 A 0 5226 A 2024-02-13 2028-09-19 Common Stock 5226 5226 D Option to Purchase Common Stock 6.50 2024-02-13 4 D 0 300000 D 2018-11-21 2028-11-21 Common Stock 300000 0 D Option to Purchase Common Stock 1.92 2024-02-13 4 A 0 300000 A 2024-02-13 2028-11-21 Common Stock 300000 300000 D Option to Purchase Common Stock 8.00 2024-02-13 4 D 0 450000 D 2021-06-11 2031-06-11 Common Stock 450000 0 D Option to Purchase Common Stock 1.92 2024-02-13 4 A 0 450000 A 2024-02-13 2031-06-11 Common Stock 450000 450000 D Option to Purchase Common Stock 4.57 2024-02-13 4 D 0 2000000 D 2031-07-19 Common Stock 2000000 0 D Option to Purchase Common Stock 1.92 2024-02-13 4 A 0 2000000 A 2031-07-19 Common Stock 2000000 2000000 D Option to Purchase Common Stock 2.54 2024-02-13 4 D 0 350000 D 2032-08-25 Common Stock 350000 0 D Option to Purchase Common Stock 1.92 2024-02-13 4 A 0 350000 A 2032-08-25 Common Stock 350000 350000 D The option vested in three equal installments on February 28, 2019, February 28, 2020 and February 28, 2021. The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. The option vested in two equal installments on July 1, 2022 and July 1, 2023. The remainder of the option vests on July 1, 2024. One third of the option vested on August 25, 2023. The remainder of the option shall vest in two equal installments on August 25, 2024 and August 25, 2025. /s/ Mark Dybul 2024-02-16